Quantum BioPharma Gains Approval for Phase 2 Trial of FSD202

Quantum Biopharma ( (TSE:QNTM) ) has issued an update.

On May 28, 2025, Quantum BioPharma announced that it received approval from the Human Ethics Review Committee in Australia to conduct a Phase 2 clinical trial of its drug FSD202 for treating nociplastic pain in patients with Idiopathic Mast Cell Activation Syndrome (MCAS). This trial aims to assess the safety and efficacy of FSD202, which contains ultra-micronized palmitoylethanolamide (PEA), over a 56-day period in 60 patients. The approval marks a significant step in Quantum BioPharma’s clinical development efforts, potentially positioning the company as a key player in addressing chronic inflammatory diseases, which are a leading cause of death globally.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company, through its subsidiary Lucid Psycheceuticals Inc., is advancing its lead compound, Lucid-MS, which targets myelin degradation in multiple sclerosis. Quantum BioPharma also holds a strategic investment portfolio and retains a significant stake in Celly Nutrition Corp., a company that markets the OTC product unbuzzd.

Average Trading Volume: 8,030

Technical Sentiment Signal: Hold

Current Market Cap: C$46.23M

For detailed information about QNTM stock, go to TipRanks’ Stock Analysis page.